Clinical resource
Prostate adenocarcinoma definitive EBRT intermediate-risk (eviQ ID 234)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for definitive EBRT of intermediate-risk prostate cancer. DoseLab's definitive prostate constraint table reproduces selected values from its organs-at-risk table, keeping eviQ's citation for each.
Why this is useful
Organ constraints for both moderately hypofractionated (20 fx, from CHHiP) and conventional (39–40 fx) definitive prostate treatment, each footnoted to its source.
Reference details
- Title
- Prostate adenocarcinoma definitive EBRT intermediate-risk (eviQ ID 234)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 234
- Version
- v.7 — last reviewed 7 November 2024; review due 31 December 2026
- Year
- 2024
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, Dose Constraints, Hypofractionation, Protocols
- Fractionation context
- 60 Gy/20 fx or 78–80 Gy/39–40 fx
- Last reviewed by DoseLab
- 2026-09-22